Markus Renschler, Sr. VP, Oncology Clinical Dev at Pharmacyclics, holds 1.39K shares in Pharmacyclics (Ticker: PCYC), holds 1.10M shares in Cyteir Therapeutics (Ticker: CYT). Most recently, Markus Renschler ― shares of Pharmacyclics on ― for an estimated value of ―.

See the Hottest Stocks Based on Insider Trading >

Markus Renschler
Pharmacyclics (PCYC)
Sr. VP, Oncology Clinical Dev

Not Ranked

Ranked #27,315 out of 98,624 Corporate Insiders

Markus Renschler has not reported sufficient informative transactions and therefore cannot be ranked.

Time Frame

1 Year

Compare to

No Benchmark

How are Insiders Ranked?

Insider Holdings

Markus Renschler does not currently own shares as a corporate insider.

A breakdown of Markus Renschler's holdings

See the Top Stocks by Insiders

Insider Roles

Markus Renschler does not currently hold a role as a corporate insider.

Roles that Markus Renschler holds in companies

See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:

Cyteir Therapeutics
(CYT)

Rating:Informative Buy

Date:Dec 23, 2022 - Dec 23, 2023

Return:+116.30%

The most profitable trade made by Markus Renschler

See the Latest Stocks Traded by Insiders

Markus Renschler's Trading History

PCYC

Pharmacyclics

―

CYT

Cyteir Therapeutics

Mar 05, 2024

―

Informative Buy

35.00K

$3.32M

List of latest transactions for each holding click on a transaction to see Markus Renschler's performance on stock

See All Insider Trading from Today

Markus Renschler insider profile FAQ

What is the percentage of profitable transactions made by Markus Renschler?

The percentage of profitable transactions made by Markus Renschler is ―.

What is the average return per transaction made by Markus Renschler?

The average return per transaction made by Markus Renschler is ―.

What stocks does Markus Renschler hold?

Markus Renschler holds: PCYC, CYT stocks.

What was Markus Renschler’s latest transaction?

Markus Renschler latest transaction was an Uninformative Buy of ―.

What was Markus Renschler's most profitable transaction?

Markus Renschler’s most profitable transaction was an Informative Buy of CYT stock on December 23, 2022. The return on the trade was 116.30%.

What is Markus Renschler's role in Pharmacyclics?

Markus Renschler's role in Pharmacyclics is Sr. VP, Oncology Clinical Dev.

How can I follow the stock ratings of top corporate insiders?

Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

Markus Renschler Insider Profile

Markus Renschler Pharmacyclics (PCYC)Sr. VP, Oncology Clinical Dev